Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $2.4 million.

  • ImmunoTech's Cash & Current Investments fell 6655.1% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 6655.1%. This contributed to the annual value of $4.0 million for FY2024, which is 6957.15% down from last year.
  • Per ImmunoTech's latest filing, its Cash & Current Investments stood at $2.4 million for Q3 2025, which was down 6655.1% from $835000.0 recorded in Q2 2025.
  • In the past 5 years, ImmunoTech's Cash & Current Investments ranged from a high of $28.4 million in Q2 2023 and a low of $835000.0 during Q2 2025
  • In the last 3 years, ImmunoTech's Cash & Current Investments had a median value of $8.6 million in 2024 and averaged $10.2 million.
  • In the last 5 years, ImmunoTech's Cash & Current Investments tumbled by 6457.14% in 2024 and then plummeted by 9170.06% in 2025.
  • ImmunoTech's Cash & Current Investments (Quarter) stood at $13.1 million in 2023, then tumbled by 69.57% to $4.0 million in 2024, then crashed by 39.43% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $835000.0 for Q2 2025, and $2.2 million during Q1 2025.